A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This is a study to compare the efficacy and safety of 3 doses of DR-2031 to placebo when used
as "add-on" therapy for prostate cancer patients with hot flashes following surgical or
medical castration. All prostate cancer therapy must be stable for at least 45 days before
entering the study and must remain stable throughout this 12-week study. Patients will
maintain a daily paper diary to record the frequency and severity of hot flashes during the
treatment period.